beclabuvir
Sign in to saveAlso known as BCV
Beclabuvir (also known by the research name BMS-791325; abbreviated BCV) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection that has been studied in clinical trials. In February 2017, Bristol-Myers Squibb began sponsoring a post-marketing trial of beclabuvir, in combination with asunaprevir and daclatasvir, to study the combination's safety profile with regard to liver function. From February 2014 to November 2016, a phase II clinical trial was conducted on the combination of asunaprevir/daclatasvir/beclabuvir (beclabuvir is referred to as BMS-791325 in the trial) on p
~3 min read
Encyclopedic overview
2 sectionsContents
- Pharmacology
- References
{{Infobox drug | drug_name = | IUPAC_name = (1aR,12bS)-8-Cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-{[(1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl}-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a] [2]benzazepine-5-carboxamide | image = Beclabuvir.svg | image_class = skin-invert-image | width = 250 | alt = | caption =
| tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = IND | routes_of_administration =
Excerpted from Wikipedia’s “beclabuvir” article, available under the CC BY-SA 4.0 licence.